| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
CH3OCO-D-CHA-Gly-Arg-pNA acetate targets factor Xa (FXa), a serine protease that plays a central role in the coagulation cascade by converting prothrombin to thrombin. The compound serves as a substrate for factor Xa rather than an inhibitor. The peptide sequence is specifically recognized and cleaved by factor Xa at the Arg-pNA bond. This substrate is used to measure factor Xa activity in biochemical assays, enabling the study of coagulation and the screening of factor Xa inhibitors.
|
|---|---|
| ln Vitro |
In vitro, CH3OCO-D-CHA-Gly-Arg-pNA acetate functions as a chromogenic substrate for factor Xa activity assays. Upon cleavage by factor Xa, the substrate releases p-nitroaniline (pNA), which can be detected by measuring absorbance at 405 nm. The rate of pNA release is directly proportional to factor Xa activity, allowing for quantitative measurement of enzyme activity. The substrate is used in kinetic and endpoint measurements for the study of factor Xa function and inhibition.
|
| ln Vivo |
In vivo activity data for CH3OCO-D-CHA-Gly-Arg-pNA acetate are not applicable, as the compound is a research reagent used exclusively for in vitro biochemical assays rather than a therapeutic agent. The compound is not intended for administration to animals or humans and has no in vivo pharmacological effects. Its utility is limited to laboratory settings for measuring factor Xa activity in plasma or purified enzyme preparations.
|
| Enzyme Assay |
The in vitro enzyme assay for CH3OCO-D-CHA-Gly-Arg-pNA acetate typically involves incubating the substrate with factor Xa in assay buffer (e.g., Tris-HCl, pH 7.4-8.0, containing calcium ions) at 37°C. Varying concentrations of the substrate (typically 0.01-5 mM) are used to determine kinetic parameters. The reaction is monitored continuously by measuring absorbance at 405 nm, and the initial rate of pNA release is calculated. For inhibition studies, factor Xa inhibitors are pre-incubated with the enzyme before substrate addition.
|
| Cell Assay |
For in vitro cell-based assays, CH3OCO-D-CHA-Gly-Arg-pNA acetate is not typically used in cell culture, as it is designed for biochemical assays with purified enzyme or plasma. However, the substrate can be used to measure factor Xa activity in cell lysates or conditioned media from cells expressing factor Xa. Cells are cultured and lysed, and the lysate is incubated with the substrate in assay buffer. Absorbance at 405 nm is measured to determine factor Xa activity in the sample.
|
| Animal Protocol |
In vivo animal studies are not applicable for CH3OCO-D-CHA-Gly-Arg-pNA acetate, as the compound is a research reagent for in vitro use only. The compound is not administered to animals for efficacy or pharmacokinetic studies. Its use is confined to laboratory experiments for measuring factor Xa activity in plasma samples obtained from animal studies or clinical trials.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CH3OCO-D-CHA-Gly-Arg-pNA acetate have not been characterized, as the compound is a research reagent not intended for in vivo use. The molecular weight is 622.67 g/mol and the molecular formula is C₂₇H₄₂N₈O₉. The compound should be stored as a powder at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. Solubility information is available from the supplier.
|
| Toxicity/Toxicokinetics |
Toxicology data for CH3OCO-D-CHA-Gly-Arg-pNA acetate are not applicable, as the compound is a research reagent for in vitro use only. The compound is not intended for human or animal administration. Standard laboratory safety precautions should be followed when handling the compound. It is not classified as a drug substance and has not undergone toxicological evaluation for therapeutic applications.
|
| References | |
| Additional Infomation |
CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa widely used in coagulation research. It enables the quantitative measurement of factor Xa activity in biochemical assays and is valuable for screening factor Xa inhibitors. The compound is intended for research use only and is not approved for diagnostic or therapeutic applications. It is available as a high-purity research reagent for laboratory studies.
|
| Molecular Formula |
C27H42N8O9
|
|---|---|
| Molecular Weight |
622.67
|
| Exact Mass |
622.307
|
| CAS # |
80895-10-9
|
| PubChem CID |
16218538
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.855
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
44
|
| Complexity |
923
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=O)O.COC(=O)N[C@H](CC1CCCCC1)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-]
|
| InChi Key |
QXWRKXQCMBOLJR-CMXBXVFLSA-N
|
| InChi Code |
InChI=1S/C25H38N8O7.C2H4O2/c1-40-25(37)32-20(14-16-6-3-2-4-7-16)22(35)29-15-21(34)31-19(8-5-13-28-24(26)27)23(36)30-17-9-11-18(12-10-17)33(38)39;1-2(3)4/h9-12,16,19-20H,2-8,13-15H2,1H3,(H,29,35)(H,30,36)(H,31,34)(H,32,37)(H4,26,27,28);1H3,(H,3,4)/t19-,20+;/m0./s1
|
| Chemical Name |
acetic acid;methyl N-[(2R)-3-cyclohexyl-1-[[2-[[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6060 mL | 8.0299 mL | 16.0599 mL | |
| 5 mM | 0.3212 mL | 1.6060 mL | 3.2120 mL | |
| 10 mM | 0.1606 mL | 0.8030 mL | 1.6060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
